• TF2 and 68 Ga-IMP-288
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Medullary Thyroid Carcinoma
Conditions
Medullary Thyroid Carcinoma
Trial Timeline
Jan 1, 2013 → Dec 1, 2016
NCT ID
NCT01730638About • TF2 and 68 Ga-IMP-288
• TF2 and 68 Ga-IMP-288 is a phase 1/2 stage product being developed by Gilead Sciences for Medullary Thyroid Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01730638. Target conditions include Medullary Thyroid Carcinoma.
What happened to similar drugs?
1 of 4 similar drugs in Medullary Thyroid Carcinoma were approved
Approved (1) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01730638 | Phase 1/2 | Completed |
Competing Products
9 competing products in Medullary Thyroid Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Selpercatinib + Cabozantinib + Vandetanib | Eli Lilly | Phase 3 | 44 |
| Selpercatinib | Eli Lilly | Phase 1/2 | 36 |
| Pralsetinib + Cabozantinib + Vandetanib | Roche | Phase 3 | 32 |
| Caprelsa | Sanofi | Pre-clinical | 26 |
| Vandetanib 300mg | Sanofi | Phase 1/2 | 32 |
| Vandetanib | Sanofi | Phase 3 | 40 |
| vandetanib + omeprazole + ranitidine | Sanofi | Phase 1 | 29 |
| Cabozantinib (XL184) 140 mg + Cabozantinib (XL184) 60 mg + Placebo tablet + Placebo capsule | Exelixis | Approved | 44 |
| cabozantinib | Exelixis | Pre-clinical | 23 |